[Study on type I and type III procollagen mRNA and in situ collagen proteins expressions in hypertrophic scars after intralesional Kenalog treatment].
OBJECTIVE
This is to investigate the mechanism of effects of Kenalog on type I and III collagen syntheses and degradation in hypertrophic scars.


METHODS
Intralesional injection of Kenalog was performed on 6 patients with hypertrophic scars. On the 3rd day and 7th day after the treatment, 6 samples from the 6 patients each were collected and type I and III collagen proteins and in situ procollagen mRNA expressions were studied by means of immunohistochemistry and molecular biology.


RESULTS
On the 7th day after intralesional injection of Kenalog, type I collagen proteins reduced (P < 0.05) and type III collagen proteins did not reduced significantly (P > 0.05). On the 3rd day after intralesional injection of Kenalog, both type I and type III procollagen mRNA expressions were significantly inhibited and on the 7th day both procollagen mRNA expressions decreased further.


CONCLUSIONS
Intralesional Kenalog may inhibit type I procollagen mRNA expression more than type III. Gene expressive intensions of type I and III procollagen were higher in hypertrophic scars than in normal skin.
Xu
S
S
Research Centre of Plastic Surgery, Third Clinical School of Beijing Medical University, Beijing 100083, PR China.
Guan
B
B
Bao
W
W
D000293:Adolescent; D000328:Adult; D002056:Burns / Q000150:complications; D002648:Child; D017439:Cicatrix, Hypertrophic / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D003094:Collagen / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D008875:Middle Aged; D011347:Procollagen / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*
D011347:Procollagen; D012333:RNA, Messenger; D003094:Collagen; D014222:Triamcinolone Acetonide